newsfilter
← Latest News
GlobeNewswire·

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

  • Keros Therapeutics, Inc. announced that President & CEO Jasbir S. Seehra, Ph.D. will present at the Goldman Sachs 47th Annual Global Healthcare Conference.
  • The fireside chat presentation is scheduled for Monday, June 8, 2026, at 4:00 p.m. Eastern time.
  • A live audio webcast will be available at the provided webcast URL, with an archived replay accessible via the company's investor relations website for 90 days post-event.
  • Keros is a clinical-stage biopharmaceutical company developing therapeutics targeting disorders linked to dysfunctional TGF-ß family protein signaling.
  • Lead product candidate rinvatercept is being developed for Duchenne muscular dystrophy & amyotrophic lateral sclerosis.
  • Most advanced candidate elritercept is being developed for cytopenias, including anemia & thrombocytopenia, in patients with myelodysplastic syndrome & myelofibrosis.
  • Investor contact information includes Justin Frantz, reachable via email at jfrantz@kerostx.com or phone at 617-221-6042.